Regencell Bioscience Holdings Limited (RGC)
NEUTRALFundamental
66
Preço
$5.55
Capitalização de Mercado
-
Parte 1 · Quanto vale a empresa
Visão Geral
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$3.16B
Últimos 12 meses (até 31/12/2017)
Resultado Líquido
$112M
Últimos 12 meses (até 31/12/2017)
Fluxo de Caixa Livre
-
Capital Próprio Total
$-856M
Passivo Total
$3.70B
Rácio de Liquidez
0.83
Cobertura de Juros
-
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$3.74
Preço Atual
$5.55
Margem de Segurança
-48.3%
Intervalo de Valor Justo
$3.55 - $3.93
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
7.35
ROE
-13.1%
Rácio P/B
-
P/FCF
-
Margem Bruta
-
ROIC
9.4%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
9.4%
WACC
11.6%
ROIC − WACC
-2.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (11)
- EPS shows upward trend
- EPS CAGR 18.50%
- Price CAGR 44.61%
- ROIC 9.4%
- Operating Margin 8.6%
- Current Ratio
- Return on Tangible Assets
- Low reliance on intangibles
- Earnings Quality (OCF/NI) 3.65
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Reprovado (3)
- DCF valuation (Unknown)
- ROE -231.9%
- Net Margin Trend 3.6% vs 5.3%
Indisponível (14)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 52 |
| Ms. Michelle Chan | Financial Controller, CFO & Principal Financial Officer | - |
| Mr. Wai Hong Chung | COO, Chief Strategy Officer & Director | 47 |
| Ms. Antonia Assang | Senior Vice President of Project Management | - |
| Mr. Yat-Pui Au | Chief Business Officer | 50 |
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for RGC, sourced from Markets Gazette.
- 3/5/2026NEGATIVEDon't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
The article warns investors against buying Regencell Bioscience stock (RGC), highlighting a critical "red flag." While the company is exploring Traditional Chinese Medicine (TCM) opportunities, the exact nature and viability of these ventures remain unclear. This lack of transparency or concrete details regarding Regencell Bioscience's TCM strategies poses a significant risk. For investors, this indicates high uncertainty and potential undisclosed issues, making the stock unsuitable for speculative investment until operational details and market potential are clarified.
- 3/1/2026NEGATIVEForget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need
A recent financial analysis article advises investors to disregard general market sentiment concerning Regencell Bioscience Holdings Limited. While not providing specific details, the analysis casts the company in an unfavorable light, suggesting to "forget" it in favor of an unspecified blue-chip drug maker, described as a "boring compounder" that investors need. This implies a cautious or negative outlook on Regencell, suggesting its prospects might not be as promising as market perception, or that more solid, less volatile alternatives exist. Investors should consider this as a potential red flag, prompting further due diligence on the company before making investment decisions.
via Markets Gazette